Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experienceopen access
- Authors
- Hong, Che Ry; Kang, Hyoung Jin; Ju, Hee Young; Lee, Ji Won; Kim, Hyery; Park, Sung-Hye; Kim, Il Han; Park, Kyung Duk; Shin, Hee Young
- Issue Date
- Oct-2015
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Rhabdoid tumor; Kidney neoplasms; Soft tissue neoplasms; Neoplasm metastasis
- Citation
- CANCER RESEARCH AND TREATMENT, v.47, no.4, pp 889 - 896
- Pages
- 8
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 47
- Number
- 4
- Start Page
- 889
- End Page
- 896
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74876
- DOI
- 10.4143/crt.2013.176
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose Malignant rhabdoid tumor (MRT) is a rare and highly a ressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children's Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45 A) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74876)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.